Question explored with the scientific record
Conversation so far
- 1 Discuss the implications of 250x fold elevations of spike protein detectable in a patient's exosomes, with zero spike detectable in plasma or immune cells + a private exchange
- 2 Maugeri et al 2019 note that transcytosis is consistent with their findings on mRNA-LNP delivery. Is this transfection, rather than transcytosis?
- 3 How do later studies explain mRNA-LNP crossing the BBB?
- 4 You stated earlier that, "Transcytosis would mean the intact LNP crosses the BBB and then transfects brain cells (neurons, astrocytes, microglia) on the other side. Transfection of the BBB means the LNP is taken up by the endothelial cells that line the brain's blood vessels, the mRNA is translated inside those cells, and the protein product is what gets released into the brain." Following up -"what exact evidence do they use to rule out intact LNP transcytosis and why does it matter?
- 5 Either way, in this patient's case 2P S can be delivered across the BBB, by process of transcytosis at least. Explain the likely effects of such a process
- 6 Tell me about the likely implications for disease-injury processes once 2P spike has been transcytosed across the BBB.
- 7 Which specific injury mechanisms are most likely after BBB crossing?
- 8 to what extent are these pathways consistent with neuro-inflammation and, in effect, autoimmune encephalitic processes?
- 9 How do these mechanisms differ between infection-related encephalitis and autoimmune?
- 10 Please share more about The 2025 PANS/PANDAS review - with references - that shows autoantibodies to striatal cholinergic interneurons, Th17-driven BBB disruption, and microglial activation. What were the symptoms specificially associated with such striatal cholinergic interneurons
Answered on this page ↓
Please share more about The 2025 PANS/PANDAS review - with references - that shows autoantibodies to striatal cholinergic interneurons, Th17-driven BBB disruption, and microglial activation. What were the symptoms specificially associated with such striatal cholinergic interneurons
The short version: the 2025 review links striatal cholinergic interneuron autoantibodies to obsessive-compulsive symptoms, tics, emotional lability, and irritability, but the evidence is thin and mostly correlational.
The 2025 Frontiers review synthesizes 23 pediatric studies and reports that autoantibodies to striatal cholinergic interneurons correlate with symptom severity and neuroinflammatory markers [1]. The clinical features tied to this basal ganglia dysfunction are obsessive-compulsive symptoms, tics, emotional lability, and irritability [1]. The review also lists neurological soft signs like overflow movements, mirror movements, and impaired fine motor coordination, plus REM sleep abnormalities and periodic limb movements during REM [1].
The mechanism makes biological sense. Striatal cholinergic interneurons regulate dopamine signaling and motor control [28], and their synchronous activation triggers local serotonin release, with exaggerated coupling seen in an OCD-model mouse [27]. So an autoimmune attack on these cells plausibly produces compulsive behavior and motor symptoms. But the review itself admits the limitations: small samples, cross-sectional designs, and no standardized biomarkers [1]. Correlation with severity is not proof of causation.
The 2026 PhIP-Seq study complicates the picture. It found no disease-specific strep antibody signature in PANDAS sera and no evidence of increased neural injury, though it did find one rare anti-neural autoantibody case that improved with IVIG [2]. That study argues against a simple strep-antibody model while leaving room for rare autoantibodies.
| Symptom category | Specific features in review [1] |
|---|---|
| Psychiatric | Obsessive-compulsive symptoms, tics, emotional lability, irritability |
| Motor | Overflow movements, mirror movements, impaired fine motor coordination |
| Sleep | REM abnormalities, periodic limb movements during REM |
My call: the review proposes a plausible mechanism, but the evidence is correlational and the 2026 antibody profiling study undercuts the broader strep-autoantibody theory. Confidence: low to moderate. What would settle it: a prospective study showing these autoantibodies predict symptom onset and that removing them resolves symptoms.
Sources used 4
-
Persistence of Basal Ganglia Dysfunction in PANS/PANDAS: Review of the Evidence
This 2025 narrative review synthesizes neuroimaging, immunological, sleep, and clinical data from 23 pediatric studies (2013-2025) to support a model of persistent immune‑mediated basal ganglia dysfunction in PANS/PANDAS, characterized by caudate/putamen abnormalities, striatal …
DOI: 10.11648/j.frontiers.20250504.16 -
Antibody Profiles in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections
Ultra-deep PhIP-Seq profiling of pediatric PANDAS sera reveals no disease-specific GAS-IgG signature or epitope, no evidence of increased neural injury, and a single AGO-IgG autoantibody case whose titer declined after IVIg with symptom improvement, arguing against GAS-IgG as a …
DOI: 10.64898/2026.05.11.724168 -
Synchronous activation of striatal cholinergic interneurons induces local serotonin release
Synchronous activation of striatal cholinergic interneurons triggers local, nicotinic receptor–mediated serotonin release in the dorsal striatum, expanding the spatial footprint of 5-HT signaling and showing exaggerated coupling in an OCD-model mouse.
DOI: 10.1038/s41467-026-70359-6 -
Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson's disease
This review summarizes how striatal cholinergic interneurons regulate striatal microcircuits and dopaminergic signaling in health and Parkinson's disease, detailing muscarinic and nicotinic receptor subtype roles, disease-related alterations, and potential cholinergic-targeted t…
DOI: 10.1016/j.neuint.2019.02.019